Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
488 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05108428 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | active not recruiting | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05645146 | Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS) | active not recruiting | N/A | 360 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 |
| clinicaltrials |
| NCT05651828 | Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma | recruiting | Early Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05665504 | Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer | recruiting | — | 250 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05873439 | Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC | completed | Early Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06137274 | Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC | recruiting | Phase 2 | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06295159 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | recruiting | Phase 2 | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06327685 | Avapritinib With Decitabine in Patients With SM-AHN | recruiting | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06435351 | Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy | recruiting | Early Phase 1 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06497569 | Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer | recruiting | N/A | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | recruiting | Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06660368 | BCL2i CLAG-M in R/R Acute Myeloid Leukemia | recruiting | Phase 2 | 52 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06734130 | Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer | active not recruiting | Phase 2 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07007273 | Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma | recruiting | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07030400 | Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma | recruiting | — | 100 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07047885 | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | recruiting | Phase 1 | 38 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04069299 | Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract | completed | — | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05267587 | Preop fSRS for Resectable Brain Metastases | active not recruiting | Phase 2 | 49 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05438927 | Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer | completed | N/A | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05763563 | Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy | completed | N/A | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06104592 | Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL | recruiting | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06193486 | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | recruiting | Phase 1 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07276386 | Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma | recruiting | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07250087 | Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL | recruiting | Phase 1 | 36 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06712797 | Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center(PANTHER-PIC) | active not recruiting | N/A | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02829918 | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers | completed | Phase 2 | 54 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03071406 | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | active not recruiting | Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03384914 | Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer | active not recruiting | Phase 2 | 119 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05581030 | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06048822 | Enhancing Cancer Survivorship With Pickleball | completed | N/A | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06219174 | Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) | suspended | Phase 1 / Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06860386 | Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC | suspended | Phase 2 | 75 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02721459 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | active not recruiting | Phase 1 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02723734 | Validation Study on the Impact of Decipher® Testing - VANDAAM Study(VANDAAM) | active not recruiting | — | 240 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03495427 | PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | recruiting | Phase 2 / Phase 3 | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03514017 | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | terminated | Phase 2 | 5 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03686488 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03719768 | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | completed | Phase 1 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04319237 | Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes | completed | — | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05271630 | Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant | active not recruiting | — | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05325632 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | recruiting | Phase 2 | 53 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03501368 | Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma | completed | Phase 1 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03598309 | Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers | active not recruiting | Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04610671 | Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05558124 | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | recruiting | Phase 1 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06235281 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)(PLIGHT) | suspended | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06511882 | Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | recruiting | Phase 2 | 37 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT01659151 | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT02063724 | HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer(Adjuvant) | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials